Talimogene Laherparepvec

證據等級: L5

預測適應症: 7 個

Talimogene Laherparepvec: From Cutaneous Melanoma to Investigational Oncolytic Virotherapy Indications

One-Sentence Summary

Talimogene laherparepvec (T-VEC) is an oncolytic HSV-1-based virotherapy whose real-world approved indication is cutaneous malignant melanoma (CMM7) — but this dataset's drug.original_indications field is empty, so the model surfaced that known indication as its top "prediction" rather than a genuine repurposing candidate. The remaining candidates (leptomeningeal melanoma, uveal melanoma, glottis SCC, occult lung SCC, cloacogenic carcinoma, gallbladder adenosquamous carcinoma) are true novel signals, but none have any clinical trial or literature evidence captured in this pack, and several are anatomically incompatible with T-VEC's intratumoural injection route. A Blocking-severity data gap (missing TFDA label warnings/contraindications) also means this candidate cannot yet enter S1 safety pre-assessment.

Quick Overview

Item	Content
Original Indication	Not available in this dataset (data gap); per the model's own rationale text, T-VEC's real-world approved indication is Cutaneous Malignant Melanoma (marketed as Imlygic)
Predicted New Indication	CMM7 (Cutaneous Malignant Melanoma) — see caveat below: this is not a genuinely novel signal
TxGNN Prediction Score	99.20%
Evidence Level	L1 (per dataset; based on external/real-world evidence, not the empty trial/literature arrays in this pack)
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold (overridden from the record's "Proceed with Guardrails" — see rationale below)

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available from DrugBank for this candidate (original_moa: [Data Gap], DG002). Based on the mechanistic description embedded in the evidence pack's repurposing rationale, T-VEC is an oncolytic herpes simplex virus type-1 (HSV-1) vector that, after intratumoural injection, selectively replicates within and lyses melanoma cells while expressing GM-CSF to prime a systemic anti-tumour immune response. This mechanism is clinically validated and is the basis of T-VEC's approval as Imlygic for melanoma.

Important data quality caveat: The rank-1 "predicted" indication, CMM7, is explicitly identified in the record's own rationale text as T-VEC's core, already-approved indication — not a new repurposing opportunity. This happened because drug.original_indications was left empty in this dataset, so the pipeline could not distinguish "known indication" from "novel candidate." Its L1 evidence level and empty trial/literature counts should therefore be read as evidence-collection gaps for an already-established indication, not as a newly discovered use.

Looking past rank 1, the genuinely novel candidates cluster into two groups by anatomical/mechanistic plausibility:

Anatomically incompatible (Hold, L5): pediatric leptomeningeal melanoma, lung occult SCC, rectal cloacogenic carcinoma, gallbladder adenosquamous carcinoma — these involve CNS, undetectable, or deep-visceral lesions that cannot be reached by T-VEC's approved intratumoural injection route.
Mechanistically plausible but evidence-thin (Research Question, L3–L4): epithelioid uveal melanoma (shares melanocytic lineage and HSV-1 receptor expression, but different molecular drivers and no injectable primary site) and glottis squamous cell carcinoma (head & neck SCC, supported indirectly by T-VEC + pembrolizumab combination trials such as MASTERKEY-232, though no glottis-specific data exists in this pack).

Clinical Trial Evidence

Currently no related clinical trials registered (all evidence.clinical_trials arrays are empty across every predicted indication in this pack, including the top-ranked CMM7 entry).

Literature Evidence

Currently no related literature available (all evidence.literature arrays are empty across every predicted indication in this pack).

Norway Market Information

Currently no marketing authorization records (total_licenses: 0; market status: Not Marketed).

Cytotoxicity

T-VEC is an antineoplastic agent (approved oncolytic virotherapy for cutaneous melanoma), so this section applies.

Item	Content
Cytotoxicity Classification	Immunotherapy — Oncolytic viral therapy (HSV-1 vector engineered to express GM-CSF), not a conventional cytotoxic chemotherapy agent
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	As a live, replication-competent oncolytic virus product, handling requires biosafety precautions distinct from standard cytotoxic drug handling regulations (e.g., protection against viral shedding, dedicated waste disposal). Specific TFDA-labelled requirements are unavailable pending resolution of DG001

Safety Considerations

Please refer to the package insert for safety information. Note: TFDA label warnings, contraindications, and drug interaction data are currently a Blocking-severity data gap (DG001) — this candidate cannot proceed to S1 safety pre-assessment until this is resolved.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic case for the top-ranked indication (CMM7/cutaneous melanoma) is strong, but it reflects T-VEC's existing approved use rather than a genuine repurposing opportunity — a data registration gap, not a discovery. All truly novel candidates (ranks 2–7) carry weak evidence (L3–L5) and several are ruled out by route-of-administration incompatibility. Combined with a Blocking safety data gap, no candidate in this pack can currently justify a "Go" or "Proceed with Guardrails" decision.

To proceed, the following is needed:

Resolve DG001 (Blocking): obtain and parse the TFDA label PDF for warnings/contraindications before any S1 safety evaluation
Resolve DG002 (High): retrieve full MOA data via DrugBank API
Correct drug.original_indications to reflect T-VEC's actual approved indication (cutaneous melanoma) so future TxGNN runs don't re-surface it as a "new" prediction
For genuinely novel candidates — particularly glottis SCC — source dedicated trial/literature evidence (e.g., MASTERKEY-232 data) before advancing beyond Research Question stage
Clarify local market status/regulatory pathway, since a marketing authorization application may itself be a prerequisite before any repurposing indication can be pursued
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.